Renal Cell Carcinoma Pipeline Insight

DelveInsight’s, “Renal Cell Carcinoma Pipeline Insight, 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Renal Cell Carcinoma Understanding

Renal Cell Carcinoma Overview

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, originating from the lining of the renal tubules in the kidney. It accounts for approximately 85–90% of all kidney cancers. RCC often develops silently in the early stages, and many cases are discovered incidentally during imaging studies performed for other conditions. Common symptoms in advanced disease may include hematuria, flank pain, weight loss, fatigue, and a palpable abdominal mass. Several histological subtypes exist, with clear cell renal cell carcinoma being the most common.

The exact cause of RCC is not fully understood, but several genetic and environmental risk factors contribute to its development. Major risk factors include cigarette smoking, obesity, hypertension, chronic kidney disease, and long-term dialysis. Certain inherited conditions such as von Hippel–Lindau (VHL) disease, hereditary papillary renal carcinoma, and Birt-Hogg-Dubé syndrome also increase susceptibility. Mutations in the VHL tumor suppressor gene are particularly important in clear cell RCC and play a central role in tumor formation.

RCC develops through genetic mutations and dysregulation of cellular growth pathways within renal tubular epithelial cells. In clear cell RCC, inactivation of the VHL gene leads to accumulation of hypoxia-inducible factors (HIFs), which stimulate angiogenesis and tumor growth through increased expression of vascular endothelial growth factor (VEGF) and other growth-promoting molecules. These molecular abnormalities promote uncontrolled proliferation, resistance to apoptosis, enhanced blood vessel formation, and metastatic spread. RCC commonly metastasizes to the lungs, bones, liver, and brain.

Diagnosis of RCC typically involves imaging studies such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), which help identify renal masses and determine disease extent. Laboratory tests may include urinalysis, renal function tests, and complete blood count. Definitive diagnosis is usually confirmed through histopathological examination after biopsy or surgical removal of the tumor. Tumor staging is based on the TNM classification system and helps guide treatment decisions.

Treatment of RCC depends on tumor stage, subtype, and patient health status. Localized RCC is primarily treated with surgery, including partial nephrectomy or radical nephrectomy. Ablative therapies such as cryoablation or radiofrequency ablation may be used in selected patients. Advanced or metastatic RCC is commonly treated with targeted therapies and immunotherapies, including VEGF inhibitors, tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combinations of immunotherapy agents. Radiation therapy and supportive care may also be used for symptom management and metastatic disease control.

"Renal Cell Carcinoma Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Renal Cell Carcinoma pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Renal Cell Carcinoma Pipeline Report Highlights

The Renal Cell Carcinoma companies and academics are working to assess challenges and seek opportunities that could influence Renal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Renal Cell Carcinoma.

Renal Cell Carcinoma Emerging Drugs Analysis

This segment of the Renal Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Renal Cell Carcinoma Emerging Drugs

Casdatifan: Arcus Biosciences

Casdatifan (AB521) is an investigational oral small-molecule hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor being developed for clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. HIF-2α acts as a “master switch” that activates multiple genes under low-oxygen conditions, and in most patients with ccRCC this pathway remains abnormally activated because of VHL pathway abnormalities, promoting tumor growth and survival. Casdatifan is designed to provide deep and durable inhibition of the HIF-2α pathway, thereby blocking tumor proliferation, angiogenesis, treatment resistance, and cancer cell survival. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Renal Cell Carcinoma.

BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.

BL-B01D1 is a first-in-class EGFR × HER3 bispecific antibody-drug conjugate (ADC) developed for the treatment of advanced solid tumors, including renal cell carcinoma and other urinary system tumors. The drug is designed to simultaneously target epidermal growth factor receptor (EGFR) and HER3 expressed on tumor cells and deliver a topoisomerase I inhibitor payload directly into cancer cells, thereby promoting selective tumor cell killing while limiting systemic toxicity. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Renal Cell Carcinoma.

Orellanine: Oncorena AB

Orellanine is a first-in-class investigational therapy being developed for metastatic renal cell carcinoma, particularly clear-cell and papillary renal cell carcinoma. Orellanine is a toxin originally derived from mushrooms of the Cortinarius family and is being developed as an organ-specific chemotherapy for kidney cancer. The mechanism of action involves selective uptake into renal cancer cells through transporters highly expressed on kidney tumor cells, where it induces oxidative stress, disrupts mitochondrial function, down-regulates intracellular defense mechanisms, and ultimately triggers apoptosis and tumor cell death. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Renal Cell Carcinoma.

XmAb819: Xencor, Inc.

XmAb819 is a first-in-class, tumor-targeted XmAb® 2+1 bispecific antibody being developed for patients with advanced clear cell renal cell carcinoma (ccRCC). The drug is designed to target ENPP3, an antigen highly expressed on kidney cancer cells, while simultaneously engaging CD3 on T cells to activate targeted immune-mediated killing of tumor cells. According to the company, the XmAb 2+1 format contains two ENPP3 binding domains and one CD3 binding domain, enabling selective binding to tumor cells with high antigen density while potentially sparing normal tissues. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Renal Cell Carcinoma.

Further product details are provided in the report……..

Renal Cell Carcinoma Drug Therapeutic Assessment

This segment of the report provides insights about the different Renal Cell Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Renal Cell Carcinoma Players in Renal Cell Carcinoma

There are approx. 70+ key companies which are developing the therapies Renal Cell Carcinoma. The companies which have their Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. Phase III include, Arcus Biosciences, and others.

Renal Cell Carcinoma Clinical Trial Phases

DelveInsight’s report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Renal Cell Carcinoma Drug Route of Administration

Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Renal Cell Carcinoma Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Renal Cell Carcinoma Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Renal Cell Carcinoma Clinical Trial Activities

The Renal Cell Carcinoma pipeline report provides insights into different Renal Cell Carcinoma clinical trials within phase II, I, preclinical and discovery stage. It also analyses Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.

Renal Cell Carcinoma Pipeline Development Activities

The Renal Cell Carcinoma clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Renal Cell Carcinoma drugs.

Renal Cell Carcinoma Pipeline Report Insights

• Renal Cell Carcinoma Pipeline Analysis
• Renal Cell Carcinoma Therapeutic Assessment
• Renal Cell Carcinoma Unmet Needs
• Impact of Renal Cell Carcinoma Drugs

Renal Cell Carcinoma Pipeline Report Assessment

• Renal Cell Carcinoma Pipeline Product Profiles
• Renal Cell Carcinoma Therapeutic Assessment
• Renal Cell Carcinoma Pipeline Assessment
• Renal Cell Carcinoma Inactive drugs assessment
• Renal Cell Carcinoma Market Unmet Needs

Discover actionable insights into the Renal Cell Carcinoma market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The Renal Cell Carcinoma Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Renal Cell Carcinoma drugs?
• How many Renal Cell Carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Renal Cell Carcinoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Renal Cell Carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Renal Cell Carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Renal Cell Carcinoma Key Players

• Telix Pharmaceuticals (Innovations) Pty Limited
• Arcus Biosciences, Inc.
• Zhejiang Haichang Biotech Co., Ltd.
• Sichuan Baili Pharmaceutical Co., Ltd
• Consorzio Oncotech
• Beijing Biotech
• Imbioray (Hangzhou) Biomedicine Co., Ltd.
• Oncorena AB
• UTC Therapeutics Inc.
• Bristol-Myers Squibb
• HiberCell, Inc.
• Xencor, Inc.
• Neomorph, Inc
• Arcus Biosciences, Inc.
• Grit Biotechnology

Renal Cell Carcinoma Key Products

• 89Zr-TLX250 PET/CT
• Casdatifan
• Pazopanib
• Belzutifan
• WGI-0301
• BL-B01D1
• PF-08634404
• Axitinib
• EB-701/CA9-NK
• IBR854
• Orellanine
• UCL70805F
• BMS-986506
• HC-7366
• XmAb819
• NEO-811
• Casdatifan
• IB-T101

Explore comprehensive insights into Renal Cell Carcinoma epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.